These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11865664)

  • 21. N-oxidation of drugs associated with idiosyncratic drug reactions.
    Uetrecht J
    Drug Metab Rev; 2002 Aug; 34(3):651-65. PubMed ID: 12214672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic epoxidation of an alpha,beta-unsaturated oxime generates sensitizers of extreme potency. Are nitroso intermediates responsible?
    Bergström MA; Luthman K; Karlberg AT
    Chem Res Toxicol; 2007 Jun; 20(6):927-36. PubMed ID: 17511479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of toxic metabolites during drug development.
    Park K; Williams DP; Naisbitt DJ; Kitteringham NR; Pirmohamed M
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):425-34. PubMed ID: 15996699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism.
    Madsen KG; Olsen J; Skonberg C; Hansen SH; Jurva U
    Chem Res Toxicol; 2007 May; 20(5):821-31. PubMed ID: 17447796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies.
    Mutlib A; Jiang P; Atherton J; Obert L; Kostrubsky S; Madore S; Nelson S
    Chem Res Toxicol; 2006 Oct; 19(10):1270-83. PubMed ID: 17040096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacological aspects of drug toxicity testing.
    Ackermann E
    Pol J Pharmacol Pharm; 1980; 32(2):237-41. PubMed ID: 7454628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate.
    Ju C; Uetrecht JP
    J Pharmacol Exp Ther; 1999 Jan; 288(1):51-6. PubMed ID: 9862752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA; Obach RS
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metabolism of drugs. I. Basic metabolic reactions].
    Dyderski S; Grzymisławski M
    Pol Merkur Lekarski; 2005 Apr; 18(106):446-52. PubMed ID: 16161932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.
    Kalgutkar AS; Dalvie DK; O'Donnell JP; Taylor TJ; Sahakian DC
    Curr Drug Metab; 2002 Aug; 3(4):379-424. PubMed ID: 12093357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormesis [biological effects of low-level exposure (B.E.L.L.E.)] and dermatology.
    Thong HY; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(4):329-41. PubMed ID: 18058307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical drug properties associated with in vivo toxicological outcomes: a review.
    Price DA; Blagg J; Jones L; Greene N; Wager T
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):921-31. PubMed ID: 19519283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A quantitative high-throughput trapping assay as a measurement of potential for bioactivation.
    Meneses-Lorente G; Sakatis MZ; Schulz-Utermoehl T; De Nardi C; Watt AP
    Anal Biochem; 2006 Apr; 351(2):266-72. PubMed ID: 16473319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of urinary metabolites of xenobiotics as a non-invasive technique in toxicology.
    Breimer DD
    Arch Toxicol Suppl; 1982; 5():162-78. PubMed ID: 6954894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimizing the potential for metabolic activation as an integral part of drug design.
    Evans DC; Baillie TA
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactive oxygen species assay-based risk assessment of drug-induced phototoxicity: classification criteria and application to drug candidates.
    Onoue S; Kawamura K; Igarashi N; Zhou Y; Fujikawa M; Yamada H; Tsuda Y; Seto Y; Yamada S
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):967-72. PubMed ID: 18455898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.